Director Oren Ilan filed a Form 4 with the SEC on October 27, 2026, reporting the acquisition of 810 common shares of Roivant Sciences Ltd. on October 23, 2026, under the company's Non-Employee Director Compensation Plan.

Key Highlights

  • Transaction date: October 23, 2026, with 810 common shares acquired by director Oren Ilan.
  • Price paid: $0, as disclosed in the filing.
  • Vesting: According to the filing, the shares "was fully vested as of the grant date."
  • Plan: The award was received pursuant to the issuer's Non-Employee Director Compensation Plan, per the filing's footnote.
  • Post-transaction ownership: Ilan directly holds 124,490 common shares following the transaction, according to the filing.
  • Filing agent: The form was signed by Sam Kaplan as Attorney-in-Fact for Ilan Oren on October 27, 2026.

Director Ilan's October 2026 Share Award at Roivant Sciences

According to the Form 4 filed with the SEC on October 27, 2026, Oren Ilan, a director of Roivant Sciences Ltd. (NASDAQ:ROIV), acquired 810 common shares on October 23, 2026, at a price of $0. The filing classifies the transaction with code "A," indicating an acquisition, and notes it was made under the issuer's Non-Employee Director Compensation Plan.

The filing's footnote states the award reflects "Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date." The shares are held directly by Ilan. Following this transaction, the filing reports his total direct beneficial ownership at 124,490 common shares. No derivative securities transactions were reported in Table II of the filing.

The form was filed by one reporting person and was signed by Sam Kaplan as Attorney-in-Fact for Ilan Oren, with a signature date of October 27, 2026. No amendment date is listed, indicating this is not a correction to a prior filing.

What Was Disclosed

The filing reports a single acquisition of 810 common shares by director Oren Ilan on October 23, 2026, at $0 per share under Roivant Sciences' Non-Employee Director Compensation Plan, bringing his directly held total to 124,490 common shares.